GlassScriptPhysician profile
Kenneth J Adessa
NPI 1750348520
$15,618.97
in general payments reported to CMS, 2019-2025
51 companies · $3,393 in 2025
The $3,393 reported for 2025 was more than what 98% of Hospice and Palliative Medicine (Internal Medicine) providers received nationally (typical 2025 total: $77.77).
See the full distribution for Hospice and Palliative Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,289 · 2020: $1,621 · 2021: $2,444 · 2022: $2,161 · 2023: $2,125 · 2024: $2,584 · 2025: $3,393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,895 · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,894.85 |
| Education | $207.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,244.28 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $1,499.64 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Amgen INC. | $1,337.51 | 2019-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $1,214.70 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $1,122.35 | 2019-2024 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $1,108.80 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $859.88 | 2021-2025 | |
| Pfizer INC. | $588.36 | 2020-2025 | |
| Abbvie INC. | $565.92 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $555.81 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Novartis Pharmaceuticals Corporation | $553.78 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $501.28 | 2019-2025 | Jardiance, Tradjenta, Trijardy Xr |
| Merck Sharp & Dohme LLC | $469.44 | 2019-2022 | |
| Exact Sciences Corporation | $391.43 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $294.03 | 2022-2024 | Quviviq |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Adessa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.